VKTX jumps after VK2735 shows weight-loss maintenance on reduced dosing
Viking Therapeutics said VK2735 helped patients maintain most weight loss when moved from once-weekly dosing to every-other-week dosing.
Viking Therapeutics (VKTX) climbed on Tuesday after the biotech said its experimental obesity drug VK2735 helped patients keep most of their weight loss even when dosing was reduced from once a week to every other week. The findings may support the drug’s potential in obesity treatment, according to the company.